Connect with us


Moderna’s Coronavirus Vaccine is the Possible Solution to the World’s Worst Dilemma



Moderna’s Coronavirus Vaccine is the Possible Solution to the World’s Worst Dilemma

Moderna is the first company to develop a vaccine to make COVID-19 pandemic under our palm’s control. The 10-year-old Cambridge, Mass., company is one the company to receive funding from the US Government, in line with Operation Warp Speed, a multibillion-dollar federal movement to expedite the development of the potential vaccine.

An Experimental vaccine was developed by Moderna Inc. The Phase 1 trial was promising and the production of antibodies was evident though there were some serious side effects if the doses are not given right. Moderna Inc. developed by an experimental COVID-19 vaccine and after 12 hours of getting the second dose, Ian Haydon, the 29-year-old resident from Seatle, one of 45 participants one of the recipients began to feel chills and nausea, headaches, delirium, and muscle pain came after. With fluids and total bed rest, the symptoms were gone.

Report that was published last Tuesday by the New England Journal of Medicine found out similar findings of disadvantages of Moderna’s COVID-19 vaccine were also observed. The results of the peer-reviewed study “are promising, and they support the continued development of this vaccine,” Dr. Penny Heaton, chief executive of the Bill and Melinda Gates Medical Research Institute, stated in journal. “However, we must bear in mind the complexity of vaccine development and the work still to be done before COVID-19 vaccines are widely available.”

Its vaccine gives-off genetic material from the recovered coronavirus patient into the body of the infected recipient, which response by producing proteins will make way for the virus to infiltrate and invade the fighting cells to a host cell. The spike protein triggers the body’s immune response and inhibits the development of protective antibodies that can stop the virus to eat up the living cells in our body.

Haydon and the other study subjects have produced coronavirus antibodies in their bodies in aspects where other patients who had recovered from COVID-19 in the new Phase 1 trial, however, that does not imply that the vaccine can provide immunity to the disease as of the moment.

The vaccine was administered in three doses during the Phase 1 safety trial respectively — 25 micrograms, 100 mcg, and 250 mcg — to three groups of 15 individuals. The men and women lived in Seattle and Atlanta and were between the ages of 28 and 41.

Dr. Lisa Jackson of the Kaiser Permanente Washington Health Research Institute in Seattle has reported “no serious adverse events” or hospitalizations, for the study recipients for experienced side effects that were significantly worse after the second dose of the clinical trial.

If the Moderna vaccine will be made available around the globe, he said, “we’ll have to let everyone know in advance that your arm may hurt, and you will feel out of sorts for a day or so. We have to be aware of this too because these conditions can mimic aspect influenza or COVID itself.”



Suggested Article

Coronavirus and the reinfection dilemma

Coronavirus and the reinfection dilemma



Consecutively, three people who were vaccinated by 250 micrograms had their severe symptoms and now, Moderna is no longer operating the 250-microgram dose in its trials.

“Remember, on Day One, we won’t have enough vaccine for all of the U.S.,” Schaffner said. “We will be rolling out a vaccine program as the vaccine becomes more available, and for a considerable period of time, much of the U.S. population will not be vaccinated. We will have to continue social distancing activities.”

As Moderna looks forward to new phases of its clinical trials of the vaccine testing, Haydon’s health rate, who received the 250-mcg dose, has slowly become normal. He has started marathon training again with the hope of running his first race by the end of the year, and he periodically has his blood drawn to measure the level of antibodies.

But he does not want to take risks and be hard-headed. He still wears a mask, mostly stays inside of his residence, and washes his hands frequently “like a maniac.”

“I don’t feel protected,” he said. “My concern is actually to not get exposed, even more so than before. What if I were to catch full-blown COVID? I imagine hope for this vaccine would plummet.”

Dr. William Schaffner, an infectious disease expert at Vanderbilt University and the medical director of the National Foundation for Infectious Diseases said “It’s the first step, but it is an exciting first step. It showed that this novel technology — mRNA — can induce a substantial immune response. We trust that the immune response will correlate with protection down the road.”

A vaccine expert at Children’s Hospital of Philadelphia, Dr. Paul Offit, reported his assessment about the vaccine. “It was a small dose-range trial that showed that doses of vaccine were safe, and they induced a neutralizing antibody response similar to natural infection,” he said. “But we need a large Phase 3 trial.”

Moderna recently finished administering the recipients for Phase 2 study, and its Phase 3 trials are expected to start this month or next month.



Read more Health related articles in The Weekly Trends magazine.

  • Moderna’s Coronavirus Vaccine is the Possible Solution to the World’s Worst Dilemma

    Moderna’s Coronavirus Vaccine is the Possible Solution to the World’s Worst Dilemma

  • Moderna’s Coronavirus Vaccine is the Possible Solution to the World’s Worst Dilemma

Jade Casas is proactive quality education, human rights activist, and advocate. He was a campus journalist and an active student leader during his college years. He usually writes about leadership, entertainment, news, lifestyle, and education.

Continue Reading
1 Comment

1 Comment

  1. Pingback: Nigerian Fashion Designer Tiffany Amber Put A Touch of Couture for PPE - The Weekly Trends

Leave a Reply

Your email address will not be published. Required fields are marked *

Support Us!

Write for Us

The Weekly Trends

The Weekly Trends